
LVTX
Healthcare · Biotechnology · $45.8M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · -8.4% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 19, 2026 | Time not confirmed | -0.24 | 0.00 | +100.0% |
| Nov 26, 2025 | Time not confirmed | -0.24 | -0.27 | -10.2% |
| Aug 13, 2025 | Time not confirmed | -0.30 | -0.32 | -6.7% |
| May 19, 2025 | Before the open | -0.37 | -0.12 | +68.9% |
| Mar 18, 2025 | Before the open | -0.27 | -0.13 | +51.3% |
| Nov 14, 2024 | Before the open | -0.32 | -0.43 | -34.2% |
| Aug 20, 2024 | Before the open | -0.36 | -0.31 | +13.9% |
| May 21, 2024 | Before the open | -0.12 | -0.02 | +83.3% |
| Mar 20, 2024 | Before the open | -0.12 | -0.24 | -100.0% |
| Nov 16, 2023 | Before the open | -0.49 | -0.34 | +30.6% |
| Aug 22, 2023 | Before the open | -0.47 | -0.48 | -2.1% |
| Jun 8, 2023 | Before the open | -0.52 | -0.53 | -1.9% |
| Mar 24, 2023 | Before the open | -0.61 |
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are…
| -0.72 |
| -18.0% |
| Nov 16, 2022 | After the close | -0.13 | 0.04 | +130.8% |
| Sep 13, 2022 | After the close | -0.60 | -0.29 | +51.7% |
| May 17, 2022 | Before the open | -0.82 | -0.37 | +54.9% |
| Mar 24, 2022 | Before the open | -0.36 | -0.33 | +8.3% |
| Nov 15, 2021 | Before the open | -0.31 | -0.27 | +12.9% |
| Aug 16, 2021 | Before the open | -0.27 | -0.28 | -3.7% |
| May 20, 2021 | Before the open | -0.81 | -12.27 | -1414.8% |